Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Accenture
US Army
Chinese Patent Office
Argus Health

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,084,130

« Back to Dashboard

Which drugs does patent 7,084,130 protect, and when does it expire?

Patent 7,084,130 protects NAVSTEL and is included in one NDA.

This patent has twenty patent family members in sixteen countries.

Summary for Patent: 7,084,130
Title:Intraocular irrigating solution having improved flow characteristics
Abstract:Improved intraocular irrigating solutions are described. The solutions have enhanced viscosities that reduce the risk of damage to intraocular surgical procedures by reducing the turbulence of the solutions and dampening the movement of tissue fragments and air bubbles. The solutions preferably also have modified surface tensions that more closely resemble the surface tension of the aqueous humor.
Inventor(s): Shah; Mandar V. (Arlington, TX), Boukhny; Mikhail (Laguna Niguel, CA), Garner; William H. (Southlake, TX), Markwardt; Kerry L. (Mansfield, TX), Doshi; Uday (Randolph, NJ)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:10/240,449
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,084,130
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Drugs Protected by US Patent 7,084,130

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alcon Pharms Ltd NAVSTEL calcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate SOLUTION;IRRIGATION 022193-001 Jul 24, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,084,130

PCT Information
PCT FiledDecember 11, 2001PCT Application Number:PCT/US01/48094
PCT Publication Date:June 27, 2002PCT Publication Number: WO02/49614

International Family Members for US Patent 7,084,130

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 459337 ➤ Sign Up
Australia 2002239601 ➤ Sign Up
Australia 3960102 ➤ Sign Up
Brazil 0116353 ➤ Sign Up
Canada 2431368 ➤ Sign Up
Cyprus 1110703 ➤ Sign Up
Germany 60141477 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
QuintilesIMS
Boehringer Ingelheim
US Army
Cantor Fitzgerald
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.